The Vitamin K-Dependent Bone Protein and the Action of 1,25-Dihydroxyvitamin D3 on Bone

Paul A. Price
DOI: https://doi.org/10.1007/978-1-4613-2377-8_56
1985-01-01
Abstract:This chapter considers the evidence that the vitamin K-dependent bone protein [bone Gla protein (BGP)] mediates an aspect of the action of 1,25-dihydroxyvitamin D3 on bone. BGP is a 49-residue protein of known structure [1] which contains three residues of the vitamin Independent Ca2 +-binding amino acid, γ-carboxyglutamic acid (Gla). A general review on BGP has recently been published [2], so only the most salient of its properties will be described here. BGP is one of the most abundant bone proteins [3,4] and has been detected in all vertebrates examined to date. It is also present in serum [5]. Its structure is highly conserved [6], with over 50% of the amino acid residues unchanged in BGP from swordfish and calf bone, species which diverged about 400 million years ago. The most prominent in vitro properties of BGP are its high affinity for hydroxyapatite and its ability to retard the crystallization of hydroxyapatite from supersaturated solutions of calcium phosphate [4]. Both of these properties are lost upon thermal decarboxylation of - γ -carboxyglutamic acid to glutamic acid [7], a specific chemical modification which yields an abnormal BGP apparently identical to that produced in animals treated with a vitamin K antagonist such as warfarin [8]. BGP is synthesized in bone [9] and by cultured osteosarcoma cells with an osteoblastic phenotype [10].
What problem does this paper attempt to address?